Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRE + mitazalimab
- Development stage
- Unknown
- Lead developer
- Alligator Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
IRE + mitazalimab refers to the combination of irreversible electroporation (IRE), a non-thermal ablation technique used to destroy tumor cells, with mitazalimab, a CD40 agonist monoclonal antibody. Mitazalimab is designed to activate dendritic cells and other antigen-presenting cells via CD40 stimulation, thereby enhancing T cell-mediated anti-tumor immunity. The rationale for combining IRE with mitazalimab is that IRE can induce immunogenic cell death and release tumor antigens, while mitazalimab boosts the immune system’s ability to recognize and attack cancer cells. This combination is currently being evaluated in clinical trials for locally advanced pancreatic cancer[7]. Alligator Bioscience is developing mitazalimab.
- Other names
- IRE + mitazalimab
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on IRE + mitazalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRE + mitazalimab.